EUVIMEDEUVIMED entdecken
LeserbriefKohortenstudie

Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis”

Shi-Jie Zhang, Guiying Gao

Clinical and Molecular Hepatology · 09.11.2026

DOI: 10.3350/cmh.2026.0282 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 09.11.2026. Verfasst von Shi-Jie Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Children's Medical Center, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Confounding factors, epidemiologicMASLDSensitivity analysis

Autor:innen und Institutionen

  • Children's Medical Center, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
  • Pancreatitis Treatment Centre, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guizhou, China. gaoguiying@gmc.edu.cn.

Zitieren

APA

Zhang, S. J., & Gao, G. (2026). Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis”. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0282

Vancouver

Zhang SJ, Gao G. Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis”. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0282

BibTeX
@article{Zhang2026,
  author = {Zhang, Shi-Jie and Gao, Guiying},
  title = {Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis”},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2026.0282}
}
Kostenlos starten →